Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:17:03 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:PIRS from 2023-04-27 to 2024-04-26 - 11 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-19 12:13U:PIRSNews ReleasePieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split
2024-03-27 08:03U:PIRSNews ReleasePieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential
2023-08-17 08:02U:PIRSNews ReleasePieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
2023-07-18 09:16U:PIRSNews ReleasePieris Pharmaceuticals Provides Strategic Update and Announces Restructuring
2023-06-21 07:02U:PIRSNews ReleasePieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study
2023-06-02 16:31U:PIRSNews ReleasePieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference
2023-05-22 08:01U:PIRSNews ReleasePieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference
2023-05-21 08:03U:PIRSNews ReleasePieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference
2023-05-10 07:01U:PIRSNews ReleasePieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates
2023-05-04 08:02U:PIRSNews ReleasePieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)
2023-05-02 16:30U:PIRSNews ReleasePieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023